Scientific Reports · 2026
Sequence evidence
SLLMWITQC
SLLMWITQC
Experimental observations
The increase of NY-ESO-1 to NY-ESO-1/anti-PD-1 in R was significant, with an increase of >60% in IFNγ (Fig. 3E,F).
The increase of NY-ESO-1 to NY-ESO-1/anti-PD-1 in R was significant, with an increase of ... >100% in GrB (Fig. 3G,H).
The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4A).
The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4B).
The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4C).
The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4D).
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.
